JS

Jyotiben Subhashchandra Mehta

Active Director Director DIN 10176469
DIN 10176469 First appointment May 2023 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Jyotiben Subhashchandra Mehta

Data last updated:

Jyotiben Subhashchandra Mehta is a Director at Aks Bioscience Private Limited (since 2023). The company operates in Paper.

DIN 10176469
Primary Designation Director
Industry Paper
First Appointment 26 May 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aks Bioscience Private Limited U21001GJ2023PTC141488
Director26 May 20232023Active

Board colleagues of Jyotiben Subhashchandra Mehta

NameDINCompanyDesignation
Aarti Kishor Sharma07078930Aks Bioscience Private LimitedDirector

Directorship timeline

Open interactive timeline →
Aks Bioscience Private Limited
Premium access

Shareholding and investment profile for Jyotiben Subhashchandra Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jyotiben Subhashchandra Mehta

Jyotiben Subhashchandra Mehta currently holds 1 directorship: Aks Bioscience Private Limited (Director, since 26 May 2023).

Jyotiben Subhashchandra Mehta was first appointed on 26 May 2023 as Director at Aks Bioscience Private Limited.

The current boards of Jyotiben Subhashchandra Mehta's companies include Aarti Kishor Sharma (Aks Bioscience Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available